Does Rosuvastatin Delay Progression of Atherosclerosis in HIV

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomised double blind placebo controlled trial comparing Rosuvastatin with placebo in HIV positive people who are at intermediate cardiovascular risk.

It is possible that HIV positive people will receive a greater benefit from statins because of their higher baseline levels of inflammation. Current Australian guidelines recommend initiation of statin therapy on the basis of cholesterol level and the presence of other risk factors for heart disease (such as diabetes) but do not take into account whether a patient is infected with HIV. This study aims to determine what benefit HIV infected people will receive from starting statin therapy earlier then currently recommended.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayside Health
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Moderate cardiovascular disease (CVD) risk, (10-15% 10 year risk of CVD)

• HIV positive

• Stable combination anti-retroviral therapy (cART) with plasma HIV viral load <200copies/ml for ≥ 6 months

Exclusion Criteria:

• Recommended use of lipid lowering therapy according to Australian guidelines

• Prior use of statin, fibrate, ezetimibe within the last six months

• Contraindication to statin use